ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

650

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

June 30, 2017

Conditions

Hepatitis C Virus (HCV)

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir and dasabuvir

Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

DRUG

Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir